Eintrag weiter verarbeiten
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Gespeichert in:
| Zeitschriftentitel: | Molecular Cancer Therapeutics |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Molecular Cancer Therapeutics, 15, 2016, 12, S. 3110-3119 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Eigenmann, Miro J. Frances, Nicolas Hoffmann, Gerhard Lavé, Thierry Walz, Antje-Christine Eigenmann, Miro J. Frances, Nicolas Hoffmann, Gerhard Lavé, Thierry Walz, Antje-Christine |
|---|---|
| author |
Eigenmann, Miro J. Frances, Nicolas Hoffmann, Gerhard Lavé, Thierry Walz, Antje-Christine |
| spellingShingle |
Eigenmann, Miro J. Frances, Nicolas Hoffmann, Gerhard Lavé, Thierry Walz, Antje-Christine Molecular Cancer Therapeutics Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Cancer Research Oncology |
| author_sort |
eigenmann, miro j. |
| spelling |
Eigenmann, Miro J. Frances, Nicolas Hoffmann, Gerhard Lavé, Thierry Walz, Antje-Christine 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-16-0076 <jats:title>Abstract</jats:title> <jats:p>We quantitatively compare the efficacy of two approved EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, based on in vivo and in vitro data and show how a modeling approach can be used to scale from animal to humans. Gefitinib shows a higher tumor uptake in cancer patients, and we explored the potential impact on pharmacologic and antitumor activity in in vitro and in xenograft mice. Tumor growth inhibition was monitored, and the pharmacokinetics (PK) in plasma and tumor, as well as temporal changes of phospho-Erk (pErk) signals were examined in patient-derived tumor xenograft mice. These data were integrated in a translational PKPD model, allowing us to project an efficacious human dose, which we retrospectively compared with prescribed doses for cancer patients. In vitro experiments showed that cell-cycle arrest was similar for erlotinib and gefitinib. Similar pERK biomarker responses were obtained despite a 6.6-fold higher total tumor exposure for gefitinib. The PKPD model revealed a 3.7-fold higher in vivo potency for gefitinib, which did not translate into a lower anticipated efficacious dose in humans. The model-based dose prediction matched the recommended clinical doses well. These results suggest that despite having lower total tumor-to-plasma ratios, active drug exposure at target site is higher for erlotinib. Considering the PK properties, this translates in a 50% lower recommended daily dose of erlotinib in cancer patients. In summary, total exposure at target site is not suitable to rank compounds, and an integrated modeling and experimental approach can assess efficacy more accurately. Mol Cancer Ther; 15(12); 3110–9. ©2016 AACR.</jats:p> Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Molecular Cancer Therapeutics |
| doi_str_mv |
10.1158/1535-7163.mct-16-0076 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE2LTAwNzY |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE2LTAwNzY |
| institution |
DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 |
| imprint |
American Association for Cancer Research (AACR), 2016 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2016 |
| issn |
1535-7163 1538-8514 |
| issn_str_mv |
1535-7163 1538-8514 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
eigenmann2016combiningnonclinicalexperimentswithtranslationalpkpdmodelingtodifferentiateerlotinibandgefitinib |
| publishDateSort |
2016 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Molecular Cancer Therapeutics |
| source_id |
49 |
| title |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_unstemmed |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_full |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_fullStr |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_full_unstemmed |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_short |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_sort |
combining nonclinical experiments with translational pkpd modeling to differentiate erlotinib and gefitinib |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1535-7163.mct-16-0076 |
| publishDate |
2016 |
| physical |
3110-3119 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>We quantitatively compare the efficacy of two approved EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, based on in vivo and in vitro data and show how a modeling approach can be used to scale from animal to humans. Gefitinib shows a higher tumor uptake in cancer patients, and we explored the potential impact on pharmacologic and antitumor activity in in vitro and in xenograft mice. Tumor growth inhibition was monitored, and the pharmacokinetics (PK) in plasma and tumor, as well as temporal changes of phospho-Erk (pErk) signals were examined in patient-derived tumor xenograft mice. These data were integrated in a translational PKPD model, allowing us to project an efficacious human dose, which we retrospectively compared with prescribed doses for cancer patients. In vitro experiments showed that cell-cycle arrest was similar for erlotinib and gefitinib. Similar pERK biomarker responses were obtained despite a 6.6-fold higher total tumor exposure for gefitinib. The PKPD model revealed a 3.7-fold higher in vivo potency for gefitinib, which did not translate into a lower anticipated efficacious dose in humans. The model-based dose prediction matched the recommended clinical doses well. These results suggest that despite having lower total tumor-to-plasma ratios, active drug exposure at target site is higher for erlotinib. Considering the PK properties, this translates in a 50% lower recommended daily dose of erlotinib in cancer patients. In summary, total exposure at target site is not suitable to rank compounds, and an integrated modeling and experimental approach can assess efficacy more accurately. Mol Cancer Ther; 15(12); 3110–9. ©2016 AACR.</jats:p> |
| container_issue |
12 |
| container_start_page |
3110 |
| container_title |
Molecular Cancer Therapeutics |
| container_volume |
15 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348045675855872 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:04:57.01Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Combining+Nonclinical+Experiments+with+Translational+PKPD+Modeling+to+Differentiate+Erlotinib+and+Gefitinib&rft.date=2016-12-01&genre=article&issn=1538-8514&volume=15&issue=12&spage=3110&epage=3119&pages=3110-3119&jtitle=Molecular+Cancer+Therapeutics&atitle=Combining+Nonclinical+Experiments+with+Translational+PKPD+Modeling+to+Differentiate+Erlotinib+and+Gefitinib&aulast=Walz&aufirst=Antje-Christine&rft_id=info%3Adoi%2F10.1158%2F1535-7163.mct-16-0076&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348045675855872 |
| author | Eigenmann, Miro J., Frances, Nicolas, Hoffmann, Gerhard, Lavé, Thierry, Walz, Antje-Christine |
| author_facet | Eigenmann, Miro J., Frances, Nicolas, Hoffmann, Gerhard, Lavé, Thierry, Walz, Antje-Christine, Eigenmann, Miro J., Frances, Nicolas, Hoffmann, Gerhard, Lavé, Thierry, Walz, Antje-Christine |
| author_sort | eigenmann, miro j. |
| container_issue | 12 |
| container_start_page | 3110 |
| container_title | Molecular Cancer Therapeutics |
| container_volume | 15 |
| description | <jats:title>Abstract</jats:title> <jats:p>We quantitatively compare the efficacy of two approved EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, based on in vivo and in vitro data and show how a modeling approach can be used to scale from animal to humans. Gefitinib shows a higher tumor uptake in cancer patients, and we explored the potential impact on pharmacologic and antitumor activity in in vitro and in xenograft mice. Tumor growth inhibition was monitored, and the pharmacokinetics (PK) in plasma and tumor, as well as temporal changes of phospho-Erk (pErk) signals were examined in patient-derived tumor xenograft mice. These data were integrated in a translational PKPD model, allowing us to project an efficacious human dose, which we retrospectively compared with prescribed doses for cancer patients. In vitro experiments showed that cell-cycle arrest was similar for erlotinib and gefitinib. Similar pERK biomarker responses were obtained despite a 6.6-fold higher total tumor exposure for gefitinib. The PKPD model revealed a 3.7-fold higher in vivo potency for gefitinib, which did not translate into a lower anticipated efficacious dose in humans. The model-based dose prediction matched the recommended clinical doses well. These results suggest that despite having lower total tumor-to-plasma ratios, active drug exposure at target site is higher for erlotinib. Considering the PK properties, this translates in a 50% lower recommended daily dose of erlotinib in cancer patients. In summary, total exposure at target site is not suitable to rank compounds, and an integrated modeling and experimental approach can assess efficacy more accurately. Mol Cancer Ther; 15(12); 3110–9. ©2016 AACR.</jats:p> |
| doi_str_mv | 10.1158/1535-7163.mct-16-0076 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE2LTAwNzY |
| imprint | American Association for Cancer Research (AACR), 2016 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2016 |
| institution | DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3 |
| issn | 1535-7163, 1538-8514 |
| issn_str_mv | 1535-7163, 1538-8514 |
| language | English |
| last_indexed | 2024-03-01T18:04:57.01Z |
| match_str | eigenmann2016combiningnonclinicalexperimentswithtranslationalpkpdmodelingtodifferentiateerlotinibandgefitinib |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 3110-3119 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Molecular Cancer Therapeutics |
| source_id | 49 |
| spelling | Eigenmann, Miro J. Frances, Nicolas Hoffmann, Gerhard Lavé, Thierry Walz, Antje-Christine 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-16-0076 <jats:title>Abstract</jats:title> <jats:p>We quantitatively compare the efficacy of two approved EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, based on in vivo and in vitro data and show how a modeling approach can be used to scale from animal to humans. Gefitinib shows a higher tumor uptake in cancer patients, and we explored the potential impact on pharmacologic and antitumor activity in in vitro and in xenograft mice. Tumor growth inhibition was monitored, and the pharmacokinetics (PK) in plasma and tumor, as well as temporal changes of phospho-Erk (pErk) signals were examined in patient-derived tumor xenograft mice. These data were integrated in a translational PKPD model, allowing us to project an efficacious human dose, which we retrospectively compared with prescribed doses for cancer patients. In vitro experiments showed that cell-cycle arrest was similar for erlotinib and gefitinib. Similar pERK biomarker responses were obtained despite a 6.6-fold higher total tumor exposure for gefitinib. The PKPD model revealed a 3.7-fold higher in vivo potency for gefitinib, which did not translate into a lower anticipated efficacious dose in humans. The model-based dose prediction matched the recommended clinical doses well. These results suggest that despite having lower total tumor-to-plasma ratios, active drug exposure at target site is higher for erlotinib. Considering the PK properties, this translates in a 50% lower recommended daily dose of erlotinib in cancer patients. In summary, total exposure at target site is not suitable to rank compounds, and an integrated modeling and experimental approach can assess efficacy more accurately. Mol Cancer Ther; 15(12); 3110–9. ©2016 AACR.</jats:p> Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Molecular Cancer Therapeutics |
| spellingShingle | Eigenmann, Miro J., Frances, Nicolas, Hoffmann, Gerhard, Lavé, Thierry, Walz, Antje-Christine, Molecular Cancer Therapeutics, Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib, Cancer Research, Oncology |
| title | Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_full | Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_fullStr | Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_full_unstemmed | Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_short | Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| title_sort | combining nonclinical experiments with translational pkpd modeling to differentiate erlotinib and gefitinib |
| title_unstemmed | Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1535-7163.mct-16-0076 |